Profile

Bayard L. Powell, M.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

187 Ratings
22 Comments

Bayard L. Powell, M.D.

Director-At-Large,
Section Chief,
Professor,

Clinical Interests

Acute and Chronic Leukemia, Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Leukemia

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.S.E., Duke University, 1976
  • M.D., University of North Carolina School of Medicine, 1980
  • Residency, Internal Medicine, North Carolina Baptist Hospita, 1983
  • Fellowship, North Carolina Baptist Hospita, 1986

Board Certifications

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Internal Medicine, Medical Oncology

Memberships

  • Am Coll Of Physicians
  • Am Soc of Clinical Oncology
  • Am Soc of Hematology
  • Assn Of Med Schl Professors Of
  • Cancer & Acute Leukemia Group

NPI Number

  • 1831173954
Bayard L. Powell, M.D.

Doctor Rating

4.8 out of 5

187 Ratings
22 Comments

Bayard L. Powell, M.D.

Director-At-Large, Comprehensive Cancer Center
Section Chief, Hematology & Oncology
Professor, Hematology & Oncology
Comprehensive Cancer Center

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm

Contact Information

Academic: 336-716-7970 | Department: 336-716-4464

Media Medical Expert »

Recent Publications

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R,. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015;29(3):567-575.

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-1376.

Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015;33(11):1252-1257.

Palanisamy A, Persad P, Koty PP, Douglas LL, Stratta RJ, Rogers J, Reeves-Daniel AM, Orlando G, Farney AC, Beaty MW, Pettenati MJ, Iskandar SS, Grier DD, Kaczmorski SA, Doares WH, Gautreaux MD, Freedman BI, Powell BL. Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donor. Case Rep Nephrol. 2015;2015():821346.

Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015;39(9):945-949.

Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47-55.

Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrozek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bar C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE,. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014;32(6):548-556.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1):102-111.

Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111-115.

Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrozek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014;28(6):1252-1258.

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014;165(4):497-503.

Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014;120(7):1010-1017.

Becker H, Maharry K, Mrozek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D,. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 [letter]. Leukemia. 2014;28(8):1754-1758.

Poire X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55(7):1523-1532.

Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10):1184-1190.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20(20):5255-5264.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrozek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM,. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014;111(52):18679-84.

Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA,. miR-3151 interplays with its host gene BAALC and independently impacts on outcome of older patients with cytogenetically normal acute myeloid leukemia by direct deregulation of TP53 [abstract]. Clin Lymphoma Myeloma Leuk. 2014;14(Suppl 3):S157.

Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. Effect of young age on outcomes in pediatric acute promyelocytic leukemia (APL): North American Intergroup Study CALGB 9710 (alliance) [abstract]. Blood. 2014;124(21):2301.

Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. A comparison of outcomes between adolescents and young adults (AYA) and children with acute promyelocytic leukemia (APL): North American Intergroup Study CALGB 9710 (alliance) [abstract]. Blood. 2014;124(21):2306.

Lee JH, Rademaker AW, Powell BL, Geyer S, Larson RA, Gregory J, Hijiya N, Feusner JH. Obesity does not affect the recurrence free survival rates in children less than 20 years of age in acute promyelocytic leukemia (APL) [abstract]. Blood. 2014;124(21):957.

Baljevic M, Dumitriu B, Lee JW, Paietta E, Racevskis J, Chen C, Stein EM, Gallagher Re, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Young NS, Tallman MS. Telomere length recovery strongly predicts overall survival in acute promyelocytic leukemia [abstract]. Blood. 2014;124(21):2375.

Powell BL, Olson D, Morrell RM, Hales TL, High KP, Abraham E. Increasing clinical trials accrual at a Comprehensive Cancer Center [abstract]. Blood. 2014;124(21):1266.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL. The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Blood. 2014;124(21):3744.

Danhauer SC, Russell GB, Tedeschi RG, Jesse MT, Vishnevsky T, Daley K, Carroll S, Triplett KN, Calhoun LG, Cann A, Powell BL. A longitudinal investigation of posttraumatic growth in adult patients undergoing treatment for acute leukemia. J Clin Psychol Med Settings. 2013;20(1):13-24.

Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrozek K, Bloomfield CD, Larson RA. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119(1):90-98.

Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31(7):923-929.

Powell BL. Acute promyelocytic leukemia: progress far and wide [comment]. Blood. 2013;121(11):1925-1926.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287-4294.

Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31(17):2086-2093.

Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013;27(10):2023-2031.

Nicolini FE, Turkina A, Shen Z-X, Gallagher N, Jootar S, Powell BL, De Souza C, Zheng M, Szczudlo T, le Coutre P. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Cancer. 2012;118(1):118-126.

Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA,. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742-750.

Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012;53(5):907-914.

Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica. 2012;97(5):739-742.

High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.

Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrozek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia [letter]. Leukemia. 2012;26(7):1713-1717.

Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu Y-Z, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA,. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 2012;120(2):249-258.

Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA,. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol. 2012;30(25):3109-3118.

Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59(4):662-667.

Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR,. Treatment-influenced associations of PML-RAR alpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012;120(10):2098-2108.

Klepin HD, Powell BL. Management of myelodysplastic syndromes and acute leukaemia In: Sinclair AJ, Morley JE, Vellas B, eds. Pathy's principles and practice of geriatric medicine, vol 1. 5th ed. Oxford (UK): Wiley-Blackwell;2012: 375-385.

Blum W, Sanford B, Klisovic RB, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wegzler M, Hoke E, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) [abstract]. Blood. 2012;120(21):Abstr 44.

Whitman S, Kohlschmidt J, Maharry K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mrozek K, Mendler JH, Eisfeld A-K, Volinia S, Powell BL, Carter TH, Kolitz JE, Stone RM, Park I-K, Caligiuri MA, Marcucci G, Bloomfield CD. Adverse prognostic impact of GAS6 expression in de novo cytogenetically normal acute myeloid leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance) [abstract]. Blood. 2012;120(21):1293.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Powell BL, et al. Mutations in the TET oncogene family member 2 (TET2) gene refine the new European leukemia net risk classification of primary, cytogeinetically normal acute myeloid leukemia in adults: a Cancer and Leukemia Group B Study [abstract]. Ann Hematol. 2011;90(Suppl 1):S8.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Powell BL, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and leukemia Group B Study. J Clin Oncol. 2011;29(10):1373-1381.

Klepin HD, Danhauer SC, Tooze JA, Stott K, Daley K, Vishnevsky T, Powell BL, Mihalko SL. Exercise for older adult inpatients with acute myelogenous leukemia: a pilot study. J Geriatr Oncol. 2011;2(1):11-17.

Baer MR, George SL, Sanford BL, Mrozek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25(5):800-807.

Geller R, Tooze JA, Powell BL, Klepin H. The prevalence and prognostic significance of polypharmacy in older adults treated for acute myelogenous leukemia (AML) [abstract]. J Am Geriatr Soc. 2011;59(Suppl 1):S57.

Powell BL. Arsenic trioxide in acute promyelocytic leukemia: potion not poison [editorial]. Expert Rev Anticancer Ther. 2011;11(9):1317-1319.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Acute and Chronic Leukemia, Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Leukemia
Bayard L. Powell, M.D.

Bayard L. Powell, M.D.

Director-At-Large, Comprehensive Cancer Center
Section Chief, Hematology & Oncology
Professor, Hematology & Oncology
Comprehensive Cancer Center

Doctor Rating

4.8 out of 5

Bayard L. Powell, M.D.187 Ratings
22 Comments

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.9
CP explanations of prob/condition
4.9
CP spoke using clear language
4.9
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
5
Time CP spent with patient
4.9
Wait time at clinic
4.2



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

7/29/2015

*Dr. Powell and his staff are always professional and on time. I receive excellent care.

7/23/2015

All went well. I liked him.

7/21/2015

Dr. Powell and his entire staff are top notch.

7/1/2015

Very good.

6/26/2015

Life changing I will never forget, everyone helped me make it through ALIVE!

6/3/2015

I would definitely recommend Dr. B. Powell to anyone who needs his type of consultation and care.

5/28/2015

ALL GOOD.

4/30/2015

Very good experience. #8. 20 or 25 minute.

4/28/2015

Very impressed!

4/23/2015

*Dr. Powell & assistants take a lot of time in and prior meeting w/patient.

4/22/2015

I would recommend the doctor and the hospital to anyone.

4/22/2015

*Dr. Powell is a genuinely nice physician, he took plenty of time to explain things. I trust him to meet my needs!

4/21/2015

Dr Powell and his staff are very caring and concerned people who tend to their patients with utmost care. I am Blessed to be a Patient of his.

3/3/2015

Real teamwork

2/17/2015

Good.

2/14/2015

best ever!

2/5/2015

Most definitely I would recommend *Dr. Powell -

12/17/2014

ONly have good things to say about Dr. Powell and his staff.

12/4/2014

*Dr. Powell always is kind and caring. I've been in his care for 22 years and have never had a problem.

10/13/2014

*Dr. Powell is a good doctor.

10/4/2014

Dr. Powell and his staff are excellent

9/3/2014

Excellent care without exception.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.